• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Amryt Pharma plc

    2/14/22 8:59:21 AM ET
    $AMYT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMYT alert in real time by email
    SC 13G 1 tm226438d5_sc13g.htm SC 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     
     

    SCHEDULE 13G

     

     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. )*
     

    Amryt Pharma plc

    (Name of Issuer)
     

    Ordinary Shares, £0.06 nominal value per share

    (Title of Class of Securities)
     

    03217L106**

    (CUSIP Number)
     

    December 31, 2021

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 8 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    **There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 03217L106 has been assigned to the American Depositary Shares (“ADSs”) of the Issuer, which are quoted on the Nasdaq Global Select Market under the symbol “AMYT.” Each ADS represents 5 Ordinary Shares.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)

     

       

     

    CUSIP No. 03217L106

     

    13G Page 2 of 8 Pages

     

     

    1

    NAMES OF REPORTING PERSONS

    Rubric Capital Management LP

     

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

     

    6

    SHARED VOTING POWER

     

    17,722,340 Ordinary Shares (represented by 3,544,468 ADSs)

     

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

     

    17,722,340 Ordinary Shares (represented by 3,544,468 ADSs)

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    17,722,340 Ordinary Shares (represented by 3,544,468 ADSs)

     

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.59%

     

    12

    TYPE OF REPORTING PERSON

    PN, IA

     

             

     

       

     

    CUSIP No. 03217L106

     

    13G Page 3 of 8 Pages

     

     

    1

    NAMES OF REPORTING PERSONS

    David Rosen

     

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States of America

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

     

    6

    SHARED VOTING POWER

     

    17,722,340 Ordinary Shares (represented by 3,544,468 ADSs)

     

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

     

    17,722,340 Ordinary Shares (represented by 3,544,468 ADSs)

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    17,722,340 Ordinary Shares (represented by 3,544,468 ADSs)

     

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.59%

     

    12

    TYPE OF REPORTING PERSON

    IN

     

             

       

     

    CUSIP No. 03217L106

     

    13G Page 4 of 8 Pages

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Amryt Pharma plc (the "Issuer").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Issuer's principal executive offices are located at Dept 920a 196 High Road, Wood Green, London, United Kingdom, N22 8HH.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by:
       
      (i) Rubric Capital Management LP ("Rubric Capital"), the investment adviser to certain investment funds and/or accounts (collectively, the "Rubric Funds") that hold the Ordinary Shares (as defined in Item 2(d) below) reported herein; and
         
      (ii) David Rosen ("Mr. Rosen"), Managing Member of Rubric Capital Management GP LLC, the general partner of Rubric Capital.
         
      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the forgoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the principal business office of each of the Reporting Persons is 155 East 44th St, Suite 1630, New York, NY 10017.

     

    Item 2(c). CITIZENSHIP:
       
      Rubric Capital is a Delaware limited partnership. Mr. Rosen is a citizen of the United States of America.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Ordinary Shares, £0.06 nominal value per share (the "Ordinary Shares").

     

    Item 2(e). CUSIP NUMBER:
       
      There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 03217L106 has been assigned to the American Depositary Shares (“ADSs”) of the Issuer, which are quoted on the Nasdaq Global Market under the symbol “AMYT.” Each ADS represents 5 Ordinary Shares.

     

       

     

    CUSIP No. 03217L106

     

    13G Page 5 of 8 Pages

     

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act,
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act,
      (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act,
      (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940,
      (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),
      (g) x Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
      (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution:  _____________________

     

    Item 4. OWNERSHIP.
       
     

    The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     

    The percentage set forth in Row (11) of the cover page for each of the Reporting Persons is based on the 316,904,642 Ordinary Shares outstanding as of September 30, 2021, as disclosed in Exhibit 99.1 attached to the Company’s Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission on October 29, 2021.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Item 2.

     

       

     

    CUSIP No. 03217L106

     

    13G Page 6 of 8 Pages

     

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below the Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

       

     

    CUSIP No. 03217L106

     

    13G Page 7 of 8 Pages

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of our knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    DATED: February 14, 2022

     

    RUBRIC CAPITAL MANAGEMENT LP

     

     

    By:        /s/ Michael Nachmani      

    Name:  Michael Nachmani

    Title:    Chief Operating Officer

     

     

    /s/ David Rosen     

    DAVID ROSEN

     

       

     

    CUSIP No. 03217L106

     

    13G Page 8 of 8 Pages

     

    EXHIBIT 1

     

    JOINT ACQUISITION STATEMENT
    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    DATED: February 14, 2022

     

    RUBRIC CAPITAL MANAGEMENT LP

     

     

    By:        /s/ Michael Nachmani      

    Name:  Michael Nachmani

    Title:    Chief Operating Officer

     

     

    /s/ David Rosen     

    DAVID ROSEN

     

       

     

    Get the next $AMYT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMYT

    DatePrice TargetRatingAnalyst
    9/6/2022$19.00Buy
    Canaccord Genuity
    3/10/2022$20.00 → $18.00Buy
    HC Wainwright & Co.
    3/10/2022$9.00 → $10.00Outperform
    SVB Leerink
    11/23/2021$23.00 → $19.00Outperform
    SVB Leerink
    10/4/2021$45.00Buy
    JonesTrading
    8/19/2021$22.00Outperform
    SVB Leerink
    8/19/2021$22.00Outperform
    Cowen
    7/27/2021$29.00Buy
    H.C. Wainwright
    More analyst ratings

    $AMYT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity resumed coverage on Amryt Pharma plc with a new price target

      Canaccord Genuity resumed coverage of Amryt Pharma plc with a rating of Buy and set a new price target of $19.00

      9/6/22 8:49:27 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Amryt Pharma with a new price target

      HC Wainwright & Co. reiterated coverage of Amryt Pharma with a rating of Buy and set a new price target of $18.00 from $20.00 previously

      3/10/22 6:17:28 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Amryt Pharma with a new price target

      SVB Leerink reiterated coverage of Amryt Pharma with a rating of Outperform and set a new price target of $10.00 from $9.00 previously

      3/10/22 4:40:51 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMYT
    Leadership Updates

    Live Leadership Updates

    See more
    • Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer

      Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer DUBLIN, Ireland, and Boston MA, June 27, 2022, Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce the appointment of Dr Tracy Cunningham as Chief Medical officer (CMO) with immediate effect. Dr Cunningham joined Amryt in April 2020 as VP, Head of Development with responsibility for pre-clinical and clinical development of the Amryt portfolio. Prior to this, she held senior regional and global leadership roles in AstraZeneca, Novartis and GlaxoSmithKine. She is a graduate of the Roya

      6/27/22 7:00:00 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amryt Announces the Appointment of Sheila Frame as President Americas

      DUBLIN, Ireland, and Boston MA, April 6, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce the appointment of Sheila Frame as President Americas. Sheila will lead all aspects of product commercialization for Amryt in the Americas.  Sheila has held senior leadership roles across several specialty areas with Novartis, Bristol-Myers Squibb, UCB, and AstraZeneca and has worked and lived in North America and in Europe.  Sheila holds an MBA from Concordia University. Dr Joe Wiley, CEO of Amryt Pharma, commented: “Sheila is a very experienced

      4/6/21 2:00:00 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMYT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Amryt Pharma plc (Amendment)

      SC 13G/A - Amryt Pharma plc (0001783010) (Subject)

      4/18/23 4:15:50 PM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Amryt Pharma plc (Amendment)

      SC 13G/A - Amryt Pharma plc (0001783010) (Subject)

      2/13/23 10:24:07 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Amryt Pharma plc (Amendment)

      SC 13G/A - Amryt Pharma plc (0001783010) (Subject)

      2/10/23 4:00:19 PM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMYT
    SEC Filings

    See more
    • SEC Form EFFECT filed by Amryt Pharma plc

      EFFECT - Amryt Pharma plc (0001783010) (Filer)

      4/24/23 12:15:24 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15F-12B filed by Amryt Pharma plc

      15F-12B - Amryt Pharma plc (0001783010) (Filer)

      4/24/23 6:00:57 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Amryt Pharma plc

      EFFECT - Amryt Pharma plc (0001783010) (Filer)

      4/24/23 12:15:20 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMYT
    Financials

    Live finance-specific insights

    See more
    • Amryt Reports Q3 2022 Financial and Operational Results

      Amryt Reports Q3 2022 Financial and Operational Results 8.2% YoY revenue growth in Q3 to $61.1M - 12.5% on a constant currency basis 11th consecutive quarter of positive EBITDA generation; $12.5M in Q3 2022 Operating cash flows of $14.3M for Q3 2022 Cash of $83.4M at September 30, 2022 Mycapssa® revenues increased 26.9% QoQ to $5.7M and 292.8% YoY CHMP positive opinion for Mycapssa® for the treatment of acromegaly in the EU Pathway agreed with the FDA to initiate a Phase 3 study for NET - expected in Q1 2023 Filsuvez® European launch progressing well Significant metreleptin LATAM $8.3M tender won - revenue expected to be recognized in Q4 Reaffirming FY 2022 revenue guidance to $26

      11/3/22 7:00:00 AM ET
      $AMYT
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Amryt to Report Q3 2022 Results on November 3, 2022

      Amryt to Report Q3 2022 Results on November 3, 2022 DUBLIN, Ireland, and Boston MA, October 19, 2022, Amryt (NASDAQ:AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that its unaudited financial results for the third quarter 2022 will be released on Thursday, November 3, 2022 at 0700 ET/1100 GMT. Amryt will host a conference call and webcast for analysts and investors on November 3, 2022 at 0830 ET/1230 GMT. Webcast Player URL: https://edge.media-server.com/mmc/p/6nxxorrj Telephone Dial in details: Standard International Number + 39 (0) 02 802 0911 United States +1

      10/19/22 7:00:00 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amryt Reports Record Q2 2022 Results

      Amryt Reports Record Q2 2022 Results 9.2% YoY revenue growth in Q2 to $68.5M 35.3% YoY revenue growth in Q2 excluding impact of a sporadic LATAM order in Q2 2021 7.8% growth in metreleptin revenues YoY to $46.4M in Q2 49.9% growth in metreleptin revenues in Q2 excluding impact of a sporadic LATAM order in Q2 2021 10th consecutive quarter of positive EBITDA generation Cash of $90.7M at June 30, 2022 Filsuvez® approved in the EU for the treatment of dystrophic and junctional EB Amryt now has four growing commercial products treating rare diseases Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Stock repurchase program underway

      8/4/22 7:00:00 AM ET
      $AMYT
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals

    $AMYT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc

      ●  Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. PARMA, Italy, DUBLIN and BOSTON, MA, April 12, 2023 /PRNewswire/ -- Chiesi Farmaceutici S.p.A. ("Chiesi"), an international, research-focused biopharmaceuticals and healthcare group, today announced the completion of the acquisition of Amryt Pharma Plc ("Amryt") (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases. "We are excited to add the Amryt family to our company in this acquisition that demonstrates our commitment to ra

      4/12/23 7:58:00 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc

      Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. Parma Italy, Dublin Ireland and Boston MA, April 12, 2023 – Chiesi Farmaceutici S.p.A. ("Chiesi"), an international, research-focused biopharmaceuticals and healthcare group, today announced the completion of the acquisition of Amryt Pharma Plc ("Amryt") (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases. "We are excited to add the Amryt family to our comp

      4/12/23 7:00:00 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • High Court of Justice of England and Wales Sanctions Scheme of Arrangement

      High Court of Justice of England and Wales Sanctions Scheme of Arrangement Acquisition of Amryt Pharma by Chiesi Farmaceutici Expected to Close Mid-April 2023 Dublin, Ireland, April 3, 2023 Amryt Pharma Plc ("Amryt") (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases, is pleased to announce that the High Court of Justice of England and Wales (the "Court") has sanctioned the scheme of arrangement providing for the proposed acquisition (the "Transaction") of Amryt by Chiesi Farmaceutici S.p.A. ("Chiesi") at a hearing held on March 31, 2023. The parties expect the closing of the Transa

      4/3/23 7:00:00 AM ET
      $AMYT
      Biotechnology: Pharmaceutical Preparations
      Health Care